[1]
|
In silico drug repurposing for coronavirus (COVID-19): screening known HCV drugs against the SARS-CoV-2 spike protein bound to angiotensin-converting enzyme 2 (ACE2) (6M0J)
Molecular Diversity,
2023
DOI:10.1007/s11030-022-10469-7
|
|
|
[2]
|
Non-nucleoside structured compounds with antiviral activity—past 10 years (2010–2020)
European Journal of Medicinal Chemistry,
2022
DOI:10.1016/j.ejmech.2022.114136
|
|
|
[3]
|
In silico drug repurposing for coronavirus (COVID-19): screening known HCV drugs against the SARS-CoV-2 spike protein bound to angiotensin-converting enzyme 2 (ACE2) (6M0J)
Molecular Diversity,
2022
DOI:10.1007/s11030-022-10469-7
|
|
|
[4]
|
A Molecular Docking Approach to Evaluate the Pharmacological Properties of 1-(4-amino-1,2,5-oxadiazol-3-yl)-N'-(1-(3-hydroxyphenyl)vinyl)-5-(thiophen-2-yl)1H-1,2,3-triazole-4-carbohydrazide Treatment Candidate for Use against COVID-19
Bulletin of Biotechnology,
2022
DOI:10.51539/biotech.1110858
|
|
|
[5]
|
Non-nucleoside structured compounds with antiviral activity—past 10 years (2010–2020)
European Journal of Medicinal Chemistry,
2022
DOI:10.1016/j.ejmech.2022.114136
|
|
|
[6]
|
A Molecular Docking Approach to Evaluate the Pharmacological Properties of 1-(4-amino-1,2,5-oxadiazol-3-yl)-N'-(1-(3-hydroxyphenyl)vinyl)-5-(thiophen-2-yl)1H-1,2,3-triazole-4-carbohydrazide Treatment Candidate for Use against COVID-19
Bulletin of Biotechnology,
2022
DOI:10.51539/biotech.1110858
|
|
|
[7]
|
A Multidisciplinary Approach to Coronavirus Disease (COVID-19)
Molecules,
2021
DOI:10.3390/molecules26123526
|
|
|